摘要 |
Examples and embodiments of the present invention teach and disclose, inter alia, that the previously known extracellular matrix metallproteinase inducer protein (EMMPRIN), also known as CD147, is a signal-transducing cellular receptor for cyclophilin (CyP). Accordingly, there is disclosed methods for the treatment of HIV-infection, AIDS, AIDS-related disorders., rheumatoid arthritis (RA), connective tissue disorders, cancer or any condition characterized by local or systemic CyP release, synthesis or binding using the CyP/EMMPRIN interaction as a novel therapeutic intervention target. There is further disclosed pharmaceutical compositions including, anti-EMMPRIN antibodies, and soluble EMMPRIN proteins and peptides that act by inhibiting the CyP/EMMPRIN interaction. The present invention further provides screening assays for the identification of compounds that inhibit the CyP/EMMPRIN interaction. |